Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan
Central Asian Journal of Nephrology · 2025
DOI: 10.63946/cajn/16888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Central Asian Journal of Nephrology, 2025. Verfasst von Saltanat Tuganbekova und 13 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
The advent of targeted complement inhibitors represents a paradigm shift in managing complement-mediated nephropathies. Integrating these therapies into healthcare systems, particularly in resource-variable settings, requires strategic planning.
A national council of experts was convened in October 2024 with the purpose of obtaining a clinical expert opinion to develop practical recommendations for improving the organization and optimization of medical care for patients with C3 glomerulopathy (C3G) and IgA nephropathy (IgAN) in Kazakhstan.
The council identified critical systemic gaps, including inconsistent use of renal biopsy, lack of specialized nephropathology, absence of treatment algorithms, and fragmented patient care. A consensus was reached on key recommendations for a new national clinical protocol. These include mandating pathological confirmation, creating detailed treatment and monitoring algorithms, establishing a national registry and coordination center, and investing in specialized training for healthcare professionals.
The systematic framework proposed by the council provides an actionable roadmap to overcome barriers to care. This model ensures equitable patient access to novel therapies and may serve as a blueprint for other nations navigating the integration of advanced treatments into clinical practice.
Zitieren
APA
Tuganbekova, S., Yertlessova, G., Kabulbayev, K., Botabayeva, A., Turebekov, D., Karabayeva, A., Kanafina, S., Shaimardanova, G., Sharapov, O., Babayev, F., Tsilosani, M., Komissarov, K., Tchokhonelidze, I., & Gaipov, A. (2025). Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan. Central Asian Journal of Nephrology. https://doi.org/10.63946/cajn/16888
Vancouver
Tuganbekova S, Yertlessova G, Kabulbayev K, Botabayeva A, Turebekov D, Karabayeva A, et al. Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan. Central Asian Journal of Nephrology. 2025. doi:10.63946/cajn/16888
BibTeX
@article{Tuganbekova2025,
author = {Tuganbekova, Saltanat and Yertlessova, Gulzhan and Kabulbayev, Kairat and Botabayeva, Ainur and Turebekov, Duman and Karabayeva, Aigul and Kanafina, Sholpan and Shaimardanova, Galiya and Sharapov, Olimkhon and Babayev, Fariz and Tsilosani, Miranda and Komissarov, Kirill and Tchokhonelidze, Irma and Gaipov, Abduzhappar},
title = {Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan},
journal = {Central Asian Journal of Nephrology},
year = {2025},
doi = {10.63946/cajn/16888}
}
EUVIMED